SLC5A2 and cerebral atherosclerosis: The pathways for neuroprotective properties of SGLT2 inhibitors are: (1) inhibition of microglial activation, resulting in decreased proinflammatory factor release and neuroinflammation; (2) alleviation of cerebral atherosclerosis; (3) reduction of oxidative stress in neurons; and (4) inhibition of reactive oxygen species (ROS)‐dependent neuronal apoptosis.